[90Y]-Radiolabelled Zevalin

[90Y]-Radiolabelled Zevalin

[90Y]-radiolabelled Zevalin is indicated as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma. The benefi t of Zevalin following rituximab in combination with chemotherapy has not been established.
[90Y]-radiolabelled Zevalin is indicated for the treatment of adult patients with rituximab relapsed or refractory CD20+ follicular B-cell non-Hodgkin’s lymphoma (NHL).

Loading...

Email news feed

Insert the following characters: captcha